Joel Greenblatt’s Lexicon Pharmaceuticals LXRX Stock Holding History

Joel Greenblatt’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.7K	Buy	+13,627	New	+$26.5K	﹤0.01%	1788
2017 Q1	–	Sell	-27,102	Closed	-$375K	–	1059
2016 Q4	$375K	Sell	27,102 -20,533	-43%	-$329K	﹤0.01%	771
2016 Q3	$861K	Sell	47,635 -247,459	-84%	-$3.98M	0.01%	623
2016 Q2	$4.24M	Buy	295,094 +105,777	+56%	+$1.43M	0.05%	411
2016 Q1	$2.26M	Buy	+189,317	New	+$1.98M	0.03%	562
2015 Q2	–	Sell	-10,509	Closed	-$69K	–	984
2015 Q1	$69K	Buy	+10,509	New	+$71.8K	﹤0.01%	888

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Joel Greenblatt's LXRX Position: Q2 2026 in Review

Joel Greenblatt opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 13,627 shares worth $32.7K. The stake represents ﹤0.01% of the portfolio and ranks #1788 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in LXRX as recently as Q4 2016.

Joel Greenblatt first reported a position in LXRX in Q1 2015 and has held it in 6 quarters since. The position peaked at $4.24M in Q2 2016. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

Joel Greenblatt held 13,627 shares of Lexicon Pharmaceuticals worth $32.7K as of Q2 2026.
Lexicon Pharmaceuticals was a new Joel Greenblatt position in Q2 2026.
Lexicon Pharmaceuticals made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1788 holding.
Joel Greenblatt first reported a position in Lexicon Pharmaceuticals in Q1 2015 and has held it in 6 quarters since.
Joel Greenblatt's Lexicon Pharmaceuticals position peaked at $4.24M in Q2 2016.
148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.